Pros
offers a level of job stability that is incredibly rare in the pharmaceutical industry, primarily because its private, family-owned structure completely shields it from the volatile pressures of Wall Street. Unlike publicly traded competitors that frequently initiate mass layoffs to satisfy quarterly shareholder demands, BI operates with a long-term, generational mindset—consistently reinvesting more than 20% of its revenue directly back into R&D rather than stock buybacks or investor dividends
Cons
the company is still a massive corporate matrix subject to occasional department restructures and a somewhat slow, bureaucratic pace, full-time employees enjoy genuine peace of mind knowing their careers are tied to a robust scientific pipeline rather than a fluctuating stock ticker.